Relationship between soluble protein ST2 (sST2) levels and microvascular complications in a cohort of patients with type 1 diabetes.

Diabetes tipo 1 Diabetic macular oedema Edema macular Nefropatía Nephropathy Retinopathy Retinopatía ST2 soluble Soluble ST2 Type 1 diabetes

Journal

Endocrinologia, diabetes y nutricion
ISSN: 2530-0180
Titre abrégé: Endocrinol Diabetes Nutr (Engl Ed)
Pays: Spain
ID NLM: 101717565

Informations de publication

Date de publication:
14 Jul 2021
Historique:
received: 15 02 2021
revised: 17 05 2021
accepted: 18 05 2021
entrez: 18 7 2021
pubmed: 19 7 2021
medline: 19 7 2021
Statut: aheadofprint

Résumé

To determine the association and the prognostic value of soluble ST2 (sST2) levels in the development of diabetic retinopathy (DR), diabetic macular oedema (DMO) or diabetic nephropathy (DN), in a cohort of patients with type 1 diabetes (T1D). A total of 269 individuals with T1D (154 males and 115 females) were recruited. The overall mean age was 43.2±14.9 years, and the diabetes duration was 17.1±12.1 years. Levels of sST2 in serum were evaluated, and the presence as well as the degree of DR, DMO and DN was recorded. Additionally, other clinical and analytical parameters including demographic variables were recovered from patients' electronic health record. Ten years later, the presence and stage of DR, DMO and DN were again recorded under the same criteria. The association between previously mentioned parameters with DR and DN was analysed by univariate and multivariate logistic regression. The variables in the final multivariate models were adjusted from complete models via backward elimination and maintained only when significant. An increase of 10ng/ml in the levels of sST2 was associated with a 1.50 (1.02-2.19) and 1.48 (1.05-2.08) prevalence odds ratio (OR) in DMO and DR, respectively. There was no association between sST2 levels and DN. Meanwhile, sST2 levels did not display a prognostic effect in any of the microangiopathic diabetic complications studied. Levels of sST2 are associated with the presence of DR and DMO, they do not seem to be predictive for the development or deterioration of DR, DMO or DN.

Identifiants

pubmed: 34274305
pii: S2530-0164(21)00160-9
doi: 10.1016/j.endinu.2021.05.007
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Informations de copyright

Copyright © 2021 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Luis Forga (L)

Servicio de Endocrinología y Nutrición, Complejo hospitalario de Navarra, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. Electronic address: lforgall@cfnavarra.es.

Natalia López-Andrés (N)

Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Pamplona, Spain.

Ibai Tamayo (I)

Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain; Red de Investigación en servicios de Salud en Enfermedades Crónicas (REDISSEC), Pamplona, Spain.

Amaya Fernández-Celis (A)

Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Pamplona, Spain.

Marta García-Mouriz (M)

Servicio de Endocrinología y Nutrición, Complejo hospitalario de Navarra, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

María José Goñi (MJ)

Servicio de Endocrinología y Nutrición, Complejo hospitalario de Navarra, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

Classifications MeSH